Viking Therapeutics Stock Rises 8.79% to $37.87 on June 24, 2026
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics stock closed at $37.87 on June 24, 2026, up 8.79 percent from the previous day
- Trading volume reached $210.6 million – significantly above the average of $5.6 million
- 23 of 24 analysts recommend the stock for purchase, with a mean price target of $93.60 (as of June 29, 2026)
- RSI indicator stood at 75.03 on June 24, 2026, in the overbought zone (above 70)
- The stock crossed the 200-day line upward on June 24, 2026
- Viking Therapeutics is developing VK2809 for NASH and NAFLD in Phase IIb studies
Viking Therapeutics Inc. (VKTX) stock rose 8.79 percent to $37.87 on June 24, 2026. The closing price was thus $3.06 above the previous day's close of $34.81. During the trading session, the price moved within a range between $35.03 (intraday low) and $38.08 (intraday high).
Above-Average Trading Volume
Trading volume reached $210.6 million on June 24, 2026 – many times the average volume of $5.6 million. The opening was at $35.63.
Analyst Ratings and Price Targets
According to current data from June 29, 2026, 24 analysts rate Viking Therapeutics stock. One analyst recommends the stock with "Strong Buy", 22 analysts with "Buy" and one analyst with "Hold". No sell recommendations are present. The mean price target of analysts stands at $93.60, with a median of $95.00. The price target range spans from $83.00 (low) to $101.00 (high).
Technical Indicators in Overbought Territory
The Relative Strength Index (RSI) – a technical indicator that measures overbought or oversold market conditions – stood at 75.03 on June 24, 2026. Values above 70 indicate an overbought market condition. On June 26, 2026, the RSI declined slightly to 72.57, but remained above the 70 mark. For comparison: in mid-June 2026, the RSI moved between 36.55 (June 10) and 51.10 (June 18), indicating a neutral to slightly oversold condition.
On June 24, 2026, Viking Therapeutics stock crossed the 200-day line upward – a technical signal that market participants interpret as a potential sign of an uptrend. On this day, the stock traded at times at 33.25 euros.
About Viking Therapeutics
Viking Therapeutics Inc. is a clinical-stage biotech company focused on metabolic and endocrine diseases. The company is developing VK2809, an orally available, tissue- and receptor-selective agonist of thyroid hormone receptor beta (TRβ), which is in Phase IIb studies for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). The pipeline also includes VK5211, a selective androgen receptor modulator in Phase II studies for patients after hip fracture surgery, and VK0612, an oral drug candidate for type 2 diabetes, which is to enter Phase IIb studies.